Aucta announced FDA approval of a generic version of Trileptal®(oxcarbazepine) oral suspension
- Written by PR Newswire
PISCATAWAY, N.J., Dec. 5, 2022 /PRNewswire/ -- Aucta Pharmaceuticals, Inc. ("Aucta Pharmaceuticals"), announced today the U.S. approval of a generic version of Trileptal® (oxcarbazepine) oral suspension, 300 mg/5 mL[1]. Aucta will commercialize this product in early 2023.
Oxcarbazepine oral suspension had annual sales in the U.S. exceeding $74...














